{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:37:34Z","timestamp":1790811454619,"version":"4.1.0"},"reference-count":52,"publisher":"Scientific Foundation Spiroski (publications)","issue":"3","license":[{"start":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T00:00:00Z","timestamp":1520208000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Open Access Maced J Med Sci"],"abstract":"<jats:p>BACKGROUND: Myasthenia gravis (MG) is an autoimmune disease caused by the action of specific antibodies to the postsynaptic membrane of the neuromuscular junction, leading to impaired neuromuscular transmission. Patients with MG have an increased incidence of other autoimmune diseases.AIM: to determine the presence of other associated diseases in patients with MG.METHOD: A group of 127 patients with MG followed in 10 years period, in which the presence of other associated diseases has been analysed.RESULTS: The sex ratio is in favour of the female sex, the average age of the initial manifestation of the disease is less than 50 years, 65.4% of the patients with MG have another disease. 15.0% patients have associated another autoimmune disease. Thyroid disease is the most common associated with MG, rarely rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and other autoimmune diseases. Other diseases include hypertension, heart disease, diabetes, respiratory diseases, dyslipidemia. 10.2% of the patients are diagnosed with extrathymic tumours of various origins.CONCLUSION: Associated diseases are common in patients with MG, drawing attention to the possible common basis for their coexistence, as well as their impact on the intensity and treatment of the disease.<\/jats:p>","DOI":"10.3889\/oamjms.2018.110","type":"journal-article","created":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T08:45:51Z","timestamp":1520585151000},"page":"472-478","source":"Crossref","is-referenced-by-count":42,"title":["Myasthenia Gravis and Associated Diseases"],"prefix":"10.3889","volume":"6","author":[{"given":"Nikolina","family":"Tanovska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Novotni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slobodanka","family":"Sazdova-Burneska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Kuzmanovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojan","family":"Boshkovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Kondov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Jovanovski-Srceva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Kokareva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozalinda","family":"Isjanovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"52292","published-online":{"date-parts":[[2018,3,5]]},"reference":[{"key":"43317","doi-asserted-by":"crossref","unstructured":"Drachman DB. Myasthenia gravis. N Engl J Med. 1994; 330(25):1797\u00e2\u20ac\u201c1810. https:\/\/doi.org\/10.1056\/NEJM199406233302507PMid:8190158","DOI":"10.1056\/NEJM199406233302507"},{"key":"43318","doi-asserted-by":"crossref","unstructured":"Gilhus NE. Myasthenia gravis. N Eng J Med. 2016; 375:2570-81. https:\/\/doi.org\/10.1056\/NEJMra1602678PMid:28029925","DOI":"10.1056\/NEJMra1602678"},{"key":"43319","doi-asserted-by":"crossref","unstructured":"Juel CV. Massey MJ. Myasthenia gravis. Orphanet J Rare Dis. 2007; 2:44. https:\/\/doi.org\/10.1186\/1750-1172-2-44 PMid:17986328 PMCid:PMC2211463","DOI":"10.1186\/1750-1172-2-44"},{"key":"43320","doi-asserted-by":"crossref","unstructured":"Cavalcante P, Bernasconi P, Mantegazza R. Autoimmune mechanisms in myasthenia gravis. Curr Opin Neurol. 2012; 25:621\u00e2\u20ac\u201c629. https:\/\/doi.org\/10.1097\/WCO.0b013e328357a829 PMid:22941261","DOI":"10.1097\/WCO.0b013e328357a829"},{"key":"43321","doi-asserted-by":"crossref","unstructured":"Berrih-Aknin S. Myasthenia Gravis: paradox versus paradigm in autoimmunity. J Autoimmun. 2014;52:1-28. https:\/\/doi.org\/10.1016\/j.jaut.2014.05.001 PMid:24934596","DOI":"10.1016\/j.jaut.2014.05.001"},{"key":"43322","unstructured":"Osserman KE. Ocular myasthenia gravis. Invest Ophtalmol. 1967; 6(3):277-287."},{"key":"43323","doi-asserted-by":"crossref","unstructured":"Abt PL, Patel HJ, Marsh A, Schwartz SI. Analysis of thymectomy for myasthenia gravis in older patients: A 20-year single institution experience. J Am Coll Surg. 2001; 192:459-464. https:\/\/doi.org\/10.1016\/S1072-7515(01)00795-5","DOI":"10.1016\/S1072-7515(01)00795-5"},{"key":"43324","doi-asserted-by":"crossref","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9):1725. https:\/\/doi.org\/10.1002\/art.1780400928 PMid:9324032","DOI":"10.1002\/art.1780400928"},{"key":"43325","doi-asserted-by":"crossref","unstructured":"Aletaha D, Neogi T, Silman AJ, et al. The 2010 American College of Rheumatology\/European League Against Rheumatism Classification Criteria for Rheumatoid Arthritis. Arthritis Rheum. 2010; 62(9):2569-81. https:\/\/doi.org\/10.1002\/art.27584 PMid:20872595","DOI":"10.1002\/art.27583"},{"key":"43326","unstructured":"Anaya JM, Shoenfeld Y, Correa PA. Garcia Carasco M, Cervera R. Autoimmunity and autoimmune disease. Medellin: CIB, 2005."},{"key":"43327","doi-asserted-by":"crossref","unstructured":"Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003; 2:119-125. https:\/\/doi.org\/10.1016\/S1568-9972(03)00006-5","DOI":"10.1016\/S1568-9972(03)00006-5"},{"key":"43328","doi-asserted-by":"crossref","unstructured":"Shoenfeld Y, Isenberg DA. The mosaic of autoimmunity. Immunol Today. 1989; 10:123-126. https:\/\/doi.org\/10.1016\/0167-5699(89)90245-4","DOI":"10.1016\/0167-5699(89)90245-4"},{"key":"43329","doi-asserted-by":"crossref","unstructured":"Sardu C, Cocco E, Mereu A, et al. Population based study of 12 autoimmune diseases in Sardinia, Italy: prevalence and comorbidity. PLoS One. 2012; 7(3):e32487. https:\/\/doi.org\/10.1371\/journal.pone.0032487 PMid:22396771 PMCid:PMC3292563","DOI":"10.1371\/journal.pone.0032487"},{"key":"43330","doi-asserted-by":"crossref","unstructured":"Mao ZF, Yang LX, Mo XA, et al. Frequency of autoimmune diseases in myasthenia gravis: a systematic review. Int J Neurosci. 2011; 121(3):121-9. https:\/\/doi.org\/10.3109\/00207454.2010.539307 PMid:21142828","DOI":"10.3109\/00207454.2010.539307"},{"key":"43331","doi-asserted-by":"crossref","unstructured":"Nacu A, Andersen JB, Lisnic V, Owe JF, Gilhus NE. Complicating autoimmune diseases in myasthenia gravis: a review. Autoimmunity 2015; 48(6):362-368. https:\/\/doi.org\/10.3109\/08916934.2015.1030614 PMid:25915571 PMCid:PMC4616023","DOI":"10.3109\/08916934.2015.1030614"},{"key":"43332","doi-asserted-by":"crossref","unstructured":"Christensen PB, Jensen TS, Tsiropoulos I, et al. Associated autoimmune diseases in myasthenia gravis. Acta Neurol Scand. 1995; 91:192-195. https:\/\/doi.org\/10.1111\/j.1600-0404.1995.tb00432.x PMid:7793234","DOI":"10.1111\/j.1600-0404.1995.tb00432.x"},{"key":"43333","doi-asserted-by":"crossref","unstructured":"Gilhus NE, Nacu A, Andersen JB, Owe JF. Myasthenia gravis and risks for comorbidity. Eur J Neurol. 2014; 0:1\u00e2\u20ac\u201c7.","DOI":"10.1111\/ene.12599"},{"key":"43334","doi-asserted-by":"crossref","unstructured":"Cacho-Diaz B, Flores-Gavil\u00c3\u00a1n P, Garc\u00c3\u00ada-Ramos G, Lorenzana-Mendoza NA. Myasthenia Gravis and Its Comorbidities. J Neurol Neurophysiol. 2015; 6:317. https:\/\/doi.org\/10.4172\/2155-9562.1000317","DOI":"10.4172\/2155-9562.1000317"},{"key":"43335","doi-asserted-by":"crossref","unstructured":"Kaplan I, Blakely BT, Pavlath GK, Travis M, Blau HM. Steroids induce acetylcholine receptors on cultured human muscle: implications for myasthenia gravis. Proceedings of the National Academy of Sciences of the United States of America. 1990; 87: 8100-8104. https:\/\/doi.org\/10.1073\/pnas.87.20.8100 PMid:2236023 PMCid:PMC54900","DOI":"10.1073\/pnas.87.20.8100"},{"key":"43336","doi-asserted-by":"crossref","unstructured":"Tamer S, G\u00c3\u00bcne\u00c5\u0178 HNG, G\u00c3\u00b6k\u00c3\u00a7al E, Yolda\u00c5\u0178 TK. Coexistence of autoimmune diseases and autoantibodies in myasthenia gravis patients. Neurol India. 2016; 64:45-49. https:\/\/doi.org\/10.4103\/0028-3886.173638 PMid:26754991","DOI":"10.4103\/0028-3886.173638"},{"key":"43337","doi-asserted-by":"crossref","unstructured":"Lin YP, Iqbal U, Nguyen PA,et al. The concomitant association of thyroid disorders and myasthenia gravis. Transl Neurosci. 2017; 8:27-30. https:\/\/doi.org\/10.1515\/tnsci-2017-0006 PMid:28729915 PMCid:PMC5443889","DOI":"10.1515\/tnsci-2017-0006"},{"key":"43338","doi-asserted-by":"crossref","unstructured":"Marino M, Ricciardi R, Pinchera A, et al. Mild clinical expression of myasthenia gravis associated with autoimmune thyroid diseases. J Clin Endocrinol Metab.1997; 82:438-443. https:\/\/doi.org\/10.1210\/jc.82.2.438","DOI":"10.1210\/jc.82.2.438"},{"key":"43339","doi-asserted-by":"crossref","unstructured":"Chen YL, Yeh JH, Chiu HC. Clinical features of myasthenia gravis patients with autoimmune thyroid disease in Taiwan. Acta Neurol Scand. 2013; 127:170-4. https:\/\/doi.org\/10.1111\/j.1600-0404.2012.01693.x PMid:22725712","DOI":"10.1111\/j.1600-0404.2012.01693.x"},{"key":"43340","doi-asserted-by":"crossref","unstructured":"Kanazawa M, Shimohata T, Tanaka K, Nishizawa M. Clinical features of patients with myasthenia gravis associated with autoimmune diseases. Eur J Neurol. 2007; 14:1403-4. https:\/\/doi.org\/10.1111\/j.1468-1331.2007.01978.x PMid:17941854","DOI":"10.1111\/j.1468-1331.2007.01978.x"},{"key":"43341","doi-asserted-by":"crossref","unstructured":"Thorlacius S, Aarli JA, Riise T, Matre R, Johnsen HJ. Associated disorders in myasthenia gravis: autoimmune diseases and their relation to thymectomy. Acta Neurol Scand. 1989; 80:290-295. https:\/\/doi.org\/10.1111\/j.1600-0404.1989.tb03881.x PMid:2816285","DOI":"10.1111\/j.1600-0404.1989.tb03881.x"},{"key":"43342","doi-asserted-by":"crossref","unstructured":"Jallouli M, Saadoun D, Eymard B, et al. The association of systemic lupus erythematosus and myasthenia gravis: A series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature. J Neurol. 2012; 259:1290-7. https:\/\/doi.org\/10.1007\/s00415-011-6335-z PMid:22160434","DOI":"10.1007\/s00415-011-6335-z"},{"key":"43343","doi-asserted-by":"crossref","unstructured":"Sthoeger Z, Neiman A, Elbirt D, et al. High prevalence of systemic lupus erythematosus in 78 myasthenia gravis patients: A clinical and serologic study. Am J Med Sci. 2006; 331:4-9. https:\/\/doi.org\/10.1097\/00000441-200601000-00004 PMid:16415656","DOI":"10.1097\/00000441-200601000-00004"},{"key":"43344","doi-asserted-by":"crossref","unstructured":"Hrycek A. Systemic lupus erythematosus and myasthenia gravis. Pol Arch Med Wewn. 2009; 119:582-5. PMid:19776704","DOI":"10.20452\/pamw.773"},{"key":"43345","doi-asserted-by":"crossref","unstructured":"Vaiopoulos G, Sfikakis PP, Kapsimali V, et al. The association of systemic lupus erythematosus and myasthenia gravis. Postgrad Med J. 1994; 70(828):741-5. https:\/\/doi.org\/10.1136\/pgmj.70.828.741 PMid:7831174 PMCid:PMC2397764","DOI":"10.1136\/pgmj.70.828.741"},{"key":"43346","doi-asserted-by":"crossref","unstructured":"Park MJ, Kim YA, Lee SS, et al. Appearance of systemic lupus erythemathosus in patients with myasthenia gravis following thymectomy: two Case Reports. J Korean Med Sci. 2004; 134-6. https:\/\/doi.org\/10.3346\/jkms.2004.19.1.134 PMid:14966356 PMCid:PMC2822250","DOI":"10.3346\/jkms.2004.19.1.134"},{"key":"43347","doi-asserted-by":"crossref","unstructured":"Monden Y, Uyama T, Nakahara K et al. Clinical characteristics and prognosis of myasthenia gravis with other autoimmune diseases. Ann Thorac Surg. 1986; 41:189-192. https:\/\/doi.org\/10.1016\/S0003-4975(10)62667-7","DOI":"10.1016\/S0003-4975(10)62667-7"},{"key":"43348","doi-asserted-by":"crossref","unstructured":"T\u00c3\u00a9llez-Zenteno JF, Cardenas G, Esta-ol B, Garcia-Ramos G, Weder-Cisneros N. Associated conditions in myasthenia gravis: response to thymectomy. Eur J Neurol. 2004; 11:767\u00e2\u20ac\u201c773. https:\/\/doi.org\/10.1111\/j.1468-1331.2004.00968.x PMid:15525299","DOI":"10.1111\/j.1468-1331.2004.00968.x"},{"key":"43349","doi-asserted-by":"crossref","unstructured":"Poulas K, Koutsouraki E, Kordas G, Kokla A, Tzartos SJ. Anti-MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamine. J Neuroimmunol. 2012; 250:94-98. https:\/\/doi.org\/10.1016\/j.jneuroim.2012.05.011 PMid:22683336","DOI":"10.1016\/j.jneuroim.2012.05.011"},{"key":"43350","doi-asserted-by":"crossref","unstructured":"Owe JF, Daltveit AK, Gilhus NE. Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001. J Neurol Neurosurg Psychiatry. 2006; 77:203\u00e2\u20ac\u201c207. https:\/\/doi.org\/10.1136\/jnnp.2005.072355 PMid:16421123 PMCid:PMC2077560","DOI":"10.1136\/jnnp.2005.072355"},{"key":"43351","doi-asserted-by":"crossref","unstructured":"Shukla G, Gupta S, Goyal V, et al. Abnormal sympathetic hyper-reactivity in patients with myasthenia gravis: A prospective study. Clin Neurol Neurosurg. 2013; 115:179-186. https:\/\/doi.org\/10.1016\/j.clineuro.2012.05.013 PMid:22676958","DOI":"10.1016\/j.clineuro.2012.05.013"},{"key":"43352","doi-asserted-by":"crossref","unstructured":"Shivamurthy P, Parker MW. Cardiac manifestations of myasthenia gravis: A systematic review. IJC Metab Endocr. 2014; 5:3-6. https:\/\/doi.org\/10.1016\/j.ijcme.2014.08.003","DOI":"10.1016\/j.ijcme.2014.08.003"},{"key":"43353","doi-asserted-by":"crossref","unstructured":"Limaye K, Vallurupalli S, Lee RW. Myasthenia of the Heart. Am J Med. 2016; 129(6):10-21. https:\/\/doi.org\/10.1016\/j.amjmed.2016.01.020 PMid:26841298","DOI":"10.1016\/j.amjmed.2016.01.020"},{"key":"43354","doi-asserted-by":"crossref","unstructured":"Wakata N, Nemoto H, Konno S, et al. Myasthenia Gravis and Diabetes Mellitus. Intern Med. 2007; 46(9):557-9. https:\/\/doi.org\/10.2169\/internalmedicine.46.6237 PMid:17473488","DOI":"10.2169\/internalmedicine.46.6237"},{"key":"43355","unstructured":"Gittoes NJL, Kendall MJ, Ferner RE. Drugs and diabetes mellitus. In: Pickup J, William G, Eds. Textbook of Diabetes. 2nd ed. Bickwell Science, Massachusetts. 1997: 69.1-69.10."},{"key":"43356","doi-asserted-by":"crossref","unstructured":"Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008; 37:141\u00e2\u20ac\u201c149. https:\/\/doi.org\/10.1002\/mus.20950 PMid:18059039","DOI":"10.1002\/mus.20950"},{"key":"43357","doi-asserted-by":"crossref","unstructured":"Kim WH, Kim JH, Kim EK, et al. Myasthenia Gravis Presenting as Isolated Respiratory Failure: A Case Report. Korean J Intern Med. 2010; 25(1):101-104. https:\/\/doi.org\/10.3904\/kjim.2010.25.1.101 PMid:20195411 PMCid:PMC2829406","DOI":"10.3904\/kjim.2010.25.1.101"},{"key":"43358","doi-asserted-by":"crossref","unstructured":"Gale J, Danesh-Mayer HV. Statins can induce myasthenia gravis. J Clin Neurosci. 2014; 21:195-197. https:\/\/doi.org\/10.1016\/j.jocn.2013.11.009 PMid:24433954","DOI":"10.1016\/j.jocn.2013.11.009"},{"key":"43359","doi-asserted-by":"crossref","unstructured":"Papatestas AE, Osserman KE, Kark AE. The relationship between thymus and oncogenesis. A study of incidence of non-thymic malignancy in myasthenia gravis. Br J Cancer. 1971; 25:635-645. https:\/\/doi.org\/10.1038\/bjc.1971.79","DOI":"10.1038\/bjc.1971.79"},{"key":"43360","unstructured":"PMid:5144531 PMCid:PMC2008859"},{"key":"43361","doi-asserted-by":"crossref","unstructured":"Evoli A, Batocchi AP, Tonali P, MarcianoM. Risk of cancer in patients with myasthenia gravis. AnnNY Acad Sci. 1998; 841:742\u00e2\u20ac\u201c745. https:\/\/doi.org\/10.1111\/j.1749-6632.1998.tb11011.x","DOI":"10.1111\/j.1749-6632.1998.tb11011.x"},{"key":"43362","doi-asserted-by":"crossref","unstructured":"Monden Y, Uyama T, Kimura S, Taniki T. Extrathymic malignancy in patients with myasthenia gravis. Eur J Cancer. 1991; 27:745\u00e2\u20ac\u201c747. https:\/\/doi.org\/10.1016\/0277-5379(91)90179-H","DOI":"10.1016\/0277-5379(91)90179-H"},{"key":"43363","doi-asserted-by":"crossref","unstructured":"Pan CC, Chen PC, Wang LS, Chi KH, Chiang H. Thymoma is associated with an increased risk of second malignancy. Cancer. 2001; 92:2406\u00e2\u20ac\u201c2411. https:\/\/doi.org\/10.1002\/1097-0142(20011101)92:9<2406::AID-CNCR1589>3.0.CO;2-7","DOI":"10.1002\/1097-0142(20011101)92:9<2406::AID-CNCR1589>3.0.CO;2-7"},{"key":"43364","doi-asserted-by":"crossref","unstructured":"Levin N, Abramsky O, Lossos A, et al. Extrathymic malignancies in patients with myasthenia gravis. J Neurol Sci. 2005; 237(1-2):39-43. https:\/\/doi.org\/10.1016\/j.jns.2005.05.009","DOI":"10.1016\/j.jns.2005.05.009"},{"key":"43365","unstructured":"PMid:15990114"},{"key":"43366","doi-asserted-by":"crossref","unstructured":"Wakata N, Sugimoto H, Nomoto N, et al. Extrathymic tumors in patients with myasthenia gravis: a 35 year retrospective study. Neurologist 2006; 12:53\u00e2\u20ac\u201c55. https:\/\/doi.org\/10.1097\/01.nrl.0000195828.36108.c3 PMid:16547448","DOI":"10.1097\/01.nrl.0000195828.36108.c3"},{"key":"43367","doi-asserted-by":"crossref","unstructured":"Basta I, Pekmezovic T, Peric S, et al. Extrathymic malignancies in a defined cohort of patients with myasthenia gravis. J Neurol Sci. 2014; 346(1):80-84. https:\/\/doi.org\/10.1016\/j.jns.2014.07.060 PMid:25129207","DOI":"10.1016\/j.jns.2014.07.060"},{"key":"43368","doi-asserted-by":"crossref","unstructured":"Citterio A, Beghi E, Millul A, et al. Risk factors for tumor occurrence in patients with myasthenia gravis. J Neurol 2009; 256:1221\u00e2\u20ac\u201c7. https:\/\/doi.org\/10.1007\/s00415-009-5091-9 PMid:19330280","DOI":"10.1007\/s00415-009-5091-9"}],"container-title":["Open Access Macedonian Journal of Medical Sciences"],"original-title":[],"link":[{"URL":"https:\/\/oamjms.eu\/index.php\/mjms\/article\/download\/oamjms.2018.110\/1938","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/oamjms.eu\/index.php\/mjms\/article\/download\/oamjms.2018.110\/1970","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T07:47:14Z","timestamp":1744703234000},"score":1,"resource":{"primary":{"URL":"https:\/\/oamjms.eu\/index.php\/mjms\/article\/view\/oamjms.2018.110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,5]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,4,15]]}},"URL":"https:\/\/doi.org\/10.3889\/oamjms.2018.110","relation":{},"ISSN":["1857-9655"],"issn-type":[{"value":"1857-9655","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,5]]}}}